BRCA1 and pachyonychia congenita: Shroff et al. performed a phase II trial of rucaparib (RUCAPANC trial) for 19 patients with locally advanced/metastatic PC harboring BRCA1/BRCA2 mutation, and reported an ORR of 21.1% and disease control rate of 31.6% [87].